Related references
Note: Only part of the references are listed.FGF21 counteracts alcohol intoxication by activating the noradrenergic nervous system
Mihwa Choi et al.
CELL METABOLISM (2023)
Bile acids and the gut microbiota: metabolic interactions and impacts on disease
Stephanie L. Collins et al.
NATURE REVIEWS MICROBIOLOGY (2023)
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Rohit Loomba et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP-activated protein kinase-Caspase 6 signal axis
Lintao Song et al.
HEPATOLOGY (2022)
Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology
Claudia D. Fuchs et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2022)
Selective PPARδ agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway
Tetsuya Kouno et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2022)
Metabolic Messengers: bile acids
Alessia Perino et al.
NATURE METABOLISM (2022)
Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis
Yi Luo et al.
JHEP REPORTS (2022)
Tripartite Motif-Containing 27 Attenuates Liver Ischemia/Reperfusion Injury by Suppressing Transforming Growth Factor β-Activated Kinase 1 (TAK1) by TAK1 Binding Protein 2/3 Degradation
San-Yang Chen et al.
HEPATOLOGY (2021)
Gut microbiota in human metabolic health and disease
Yong Fan et al.
NATURE REVIEWS MICROBIOLOGY (2021)
The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer
Lulu Sun et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents
Sho Hasegawa et al.
DRUGS (2021)
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
Stephen A. Harrison et al.
NATURE MEDICINE (2021)
Drug Therapies for Chronic Cholestatic Liver Diseases
Martin Wagner et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 60 (2020)
The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic
Leiluo Geng et al.
NATURE REVIEWS ENDOCRINOLOGY (2020)
Curtailing FGF19's mitogenicity by suppressing its receptor dimerization ability
Jianlou Niu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Ursodeoxycholic acid and cancer: From chemoprevention to chemotherapy
Jean-Francois Goossens et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Paracrine-endocrine FGF chimeras as potent therapeutics for metabolic diseases
Longwei Zhao et al.
EBIOMEDICINE (2019)
Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis
Mary E. Rinella et al.
JOURNAL OF HEPATOLOGY (2019)
Paracrine Fibroblast Growth Factor 1 Functions as Potent Therapeutic Agent for Intrahepatic Cholestasis by Downregulating Synthesis of Bile Acid
Huan Lin et al.
FRONTIERS IN PHARMACOLOGY (2019)
Interaction of glucocorticoids with FXR/FGF19/FGF21-mediated ileum-liver crosstalk
Faten A. Al-Aqil et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2018)
A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis
Kris V. Kowdley et al.
HEPATOLOGY (2018)
FGF21 acts as a negative regulator of bile acid synthesis
Michelle M. Chen et al.
JOURNAL OF ENDOCRINOLOGY (2018)
Postprandial FGF19-induced phosphorylation by Src is critical for FXR function in bile acid homeostasis
Sangwon Byun et al.
NATURE COMMUNICATIONS (2018)
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
Arun Sanyal et al.
LANCET (2018)
Role of gut microbiota in atherosclerosis
Annika Lindskog Jonsson et al.
NATURE REVIEWS CARDIOLOGY (2017)
Fibroblast Growth Factor 21-Metabolic Role in Mice and Men
Harald Staiger et al.
ENDOCRINE REVIEWS (2017)
The Ascending Pathophysiology of Cholestatic Liver Disease
Peter L. M. Jansen et al.
HEPATOLOGY (2017)
Regulation of Receptor Binding Specificity of FGF9 by an Autoinhibitory Homodimerization
Yang Liu et al.
STRUCTURE (2017)
Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury
Bhavna N. Desai et al.
MOLECULAR METABOLISM (2017)
Chronic Over-expression of Fibroblast Growth Factor 21 Increases Bile Acid Biosynthesis by Opposing FGF15/19 Action
Jun Zhang et al.
EBIOMEDICINE (2017)
FGF19, FGF21, and an FGFR1/β-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia
Tian Lan et al.
CELL METABOLISM (2017)
Engineered Fibroblast Growth Factor 19 Reduces Liver Injury and Resolves Sclerosing Cholangitis in Mdr2-Deficient Mice
Mei Zhou et al.
HEPATOLOGY (2016)
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
Chiara Degirolamo et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Understanding the Physiology of FGF21
Ffolliott Martin Fisher et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 78 (2016)
Expression of fibroblast growth factor 21 in patients with biliary atresia
Dawei Li et al.
CYTOKINE (2016)
Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21
Diana Ronai Dunshee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis
Anna Baghdasaryan et al.
JOURNAL OF HEPATOLOGY (2016)
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
Gideon M. Hirschfield et al.
GASTROENTEROLOGY (2015)
Fibrates and cholestasis
Nisanne S. Ghonem et al.
HEPATOLOGY (2015)
Bile acid nuclear receptor FXR and digestive system diseases
Lili Ding et al.
ACTA PHARMACEUTICA SINICA B (2015)
FGF21 Acts Centrally to Induce Sympathetic Nerve Activity, Energy Expenditure, and Weight Loss
Bryn M. Owen et al.
CELL METABOLISM (2014)
Fibroblast Growth Factor 21 Limits Lipotoxicity by Promoting Hepatic Fatty Acid Activation in Mice on Methionine and Choline-Deficient Diets
Ffolliott M. Fisher et al.
GASTROENTEROLOGY (2014)
Fibroblast Growth Factor 21 Protects Against Acetaminophen-Induced Hepatotoxicity by Potentiating Peroxisome Proliferator-Activated Receptor Coactivator Protein-1α-Mediated Antioxidant Capacity in Mice
Dewei Ye et al.
HEPATOLOGY (2014)
Characterization of animal models for primary sclerosing cholangitis (PSC)
Peter Fickert et al.
JOURNAL OF HEPATOLOGY (2014)
A nontumorigenic variant of FGF19 treats cholestatic liver diseases
Jian Luo et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Adiponectin Mediates the Metabolic Effects of FGF21 on Glucose Homeostasis and Insulin Sensitivity in Mice
Zhuofeng Lin et al.
CELL METABOLISM (2013)
The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue
Andrew C. Adams et al.
MOLECULAR METABOLISM (2013)
Bile Acid Metabolism and Signaling
John Y. L. Chiang
COMPREHENSIVE PHYSIOLOGY (2013)
Liver Fibrosis Protects Mice From Acute Hepatocellular Injury
Eric Bourbonnais et al.
GASTROENTEROLOGY (2012)
Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice
Bo Kong et al.
HEPATOLOGY (2012)
Emerging Role of Fibroblast Growth Factors 15/19 and 21 as Metabolic Integrators in the Liver
Claudia Cicione et al.
HEPATOLOGY (2012)
A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis
Johan W. Jonker et al.
NATURE (2012)
Amelioration of Type 2 Diabetes by Antibody-Mediated Activation of Fibroblast Growth Factor Receptor 1
Ai-Luen Wu et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice
Jing Xu et al.
DIABETES (2009)
Bile Acids Activate Fibroblast Growth Factor 19 Signaling in Human Hepatocytes to Inhibit Cholesterol 7 alpha-Hydroxylase Gene Expression
Kwang-Hoon Song et al.
HEPATOLOGY (2009)
Bile acids: regulation of synthesis
John Y. L. Chiang
JOURNAL OF LIPID RESEARCH (2009)
FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response
Matthew J. Potthoff et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Signal integration by JNK and p38 MAPK pathways in cancer development
Erwin F. Wagner et al.
NATURE REVIEWS CANCER (2009)
Fibroblast Growth Factor 21 Corrects Obesity in Mice
Tamer Coskun et al.
ENDOCRINOLOGY (2008)
Hepatocyte growth factor signaling pathway inhibits cholesterol 7α-hydroxylase and bile acid synthesis in human hepatocytes
Kwang-Hoon Song et al.
HEPATOLOGY (2007)
Bile acids and cytokines inhibit the human cholesterol 7α-hydroxylase gene via the JNK/c-Jun pathway in human liver cells
Tiangang Li et al.
HEPATOLOGY (2006)
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
T Inagaki et al.
CELL METABOLISM (2005)
Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids
CD Yu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
The MAPK signalling pathways and colorectal cancer
JY Fang et al.
LANCET ONCOLOGY (2005)
Activation and signaling of the p38 MAP kinase pathway
T Zarubin et al.
CELL RESEARCH (2005)
Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis
JA Holt et al.
GENES & DEVELOPMENT (2003)
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
BL Bennett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Down-regulation of cholesterol 7α-hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway
S Gupta et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis
B Goodwin et al.
MOLECULAR CELL (2000)
Share Paper
